Characterisation of 2-HP-β-cyclodextrin-PLGA nanoparticle complexes for potential use as ocular drug delivery vehicles

Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):4097-4108. doi: 10.1080/21691401.2019.1683567.

Abstract

Aim: 2-HP-β-cyclodextrin-PLGA nanoparticle complexes were prepared to enhance the aqueous humour delivery of Triamcinolone acetonide.Materials & methods: Drug-loaded 2-HP-β-CD/PLGA nanoparticle complexes prepared by adapting a quasi-emulsion solvent evaporation technique. In vitro drug release, in vitro transcorneal permeation study, histopathological study and in vivo transcorneal penetration of PLGA nanoparticles and 2-HP-β-CD/PLGA nanoparticle complexes were evaluated. Results: Particle size distributions of 2-HP-β-CD/PLGA nanoparticle complexes were 149.4 ± 3.7 nm and presented stable system. Corneal penetration studies revealed steady sustained drug release (First-order); 2-HP-β-CD/PLGA nanoparticle complexes increased ocular bioavailability by increasing dispersion in the tear film and improving drug release. Conclusion: 2-HP-β-CD/PLGA nanoparticle complex formulation is a promising alternative to conventional eye drops.

Keywords: 2-hydroxypropyl-beta-cyclodextrin; Hydrophilicity; PLGA nanoparticles; ocular drug delivery; triamcinolone acetonide.

MeSH terms

  • 2-Hydroxypropyl-beta-cyclodextrin / chemistry*
  • Animals
  • Cornea / metabolism
  • Drug Carriers / chemistry*
  • Drug Carriers / metabolism
  • Drug Liberation
  • Eye / metabolism*
  • Nanoparticles / chemistry*
  • Polylactic Acid-Polyglycolic Acid Copolymer / chemistry*
  • Rabbits

Substances

  • Drug Carriers
  • 2-Hydroxypropyl-beta-cyclodextrin
  • Polylactic Acid-Polyglycolic Acid Copolymer